{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T13:58:07Z","timestamp":1791295087905,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,1,11]],"date-time":"2019-01-11T00:00:00Z","timestamp":1547164800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacionline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Allergy and Clinical Immunology"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.jaci.2018.12.1001","type":"journal-article","created":{"date-parts":[[2019,1,15]],"date-time":"2019-01-15T00:48:30Z","timestamp":1547513310000},"page":"1058-1066.e6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":110,"title":["The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial"],"prefix":"10.1016","volume":"143","author":[{"given":"Tilo","family":"Biedermann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Kuna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Panzner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erkka","family":"Valovirta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederic","family":"de Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorthe","family":"Thrane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja Hald","family":"Jacobsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian Sonne","family":"Stage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lone","family":"Winther","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaci.2018.12.1001_bib1","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/j.jaci.2017.03.050","article-title":"Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines\u20142016 revision","volume":"140","author":"Brozek","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib2","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1111\/all.12696","article-title":"Tree pollen allergens-an update from a molecular perspective","volume":"70","author":"Asam","year":"2015","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib3","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1111\/all.12419","article-title":"Geographic and temporal variations in pollen exposure across Europe","volume":"69","author":"Smith","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000151243","article-title":"The principle of homologous groups in regulatory affairs of allergen products\u2014a proposal","volume":"148","author":"Lorenz","year":"2008","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib5","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s40413-015-0069-9","article-title":"Molecular, proteomic and immunological parameters of allergens provide inclusion criteria for new candidates within established grass and tree homologous groups","volume":"8","author":"Heath","year":"2015","journal-title":"World Allergy Organ J"},{"key":"10.1016\/j.jaci.2018.12.1001_bib6","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/j.1398-9995.2009.02089.x","article-title":"GA(2)LEN skin test study II: clinical relevance of inhalant allergen sensitizations in Europe","volume":"64","author":"Burbach","year":"2009","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib7","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1111\/j.1398-9995.2006.01293.x","article-title":"Geographical variation in the prevalence of positive skin tests to environmental aeroallergens in the European Community Respiratory Health Survey I","volume":"62","author":"Bousquet","year":"2007","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib8","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.jaci.2015.06.036","article-title":"Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: results from a randomized double-blind, placebo-controlled phase III trial","volume":"137","author":"Demoly","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib9","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.jaci.2011.12.973","article-title":"SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial","volume":"129","author":"Durham","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib10","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1136\/archdischild-2014-306300","article-title":"Optimal management of allergic rhinitis","volume":"100","author":"Scadding","year":"2015","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.jaci.2018.12.1001_bib11","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1016\/j.clinthera.2018.02.012","article-title":"Immunotherapy with the SQ tree SLIT-tablet in adults and adolescents with allergic rhinoconjunctivitis","volume":"40","author":"M\u00e4kel\u00e4","year":"2018","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2018.12.1001_bib12","article-title":"A birch sublingual allergy immunotherapy (SLIT) tablet educes rhinoconjunctivitis symptoms when exposed to birch and oak and induces IgG4 to allergens from all trees in the birch homologous group","author":"Couroux","year":"2018","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib13","series-title":"Declaration of Helsinki\u2014ethical principles for medical research involving human subjects. Adopted by the WMA General Assembly in Helsinki (1964) and as amended by the WMA General Assembly","year":"2013"},{"key":"10.1016\/j.jaci.2018.12.1001_bib14","series-title":"ICH Harmonised Tripartite Guideline Topic E6 (R1): guideline for good clinical Practice","year":"1996"},{"key":"10.1016\/j.jaci.2018.12.1001_bib15","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1159\/000479693","article-title":"Bioavailability of house dust mite allergens in sublingual allergy tablets is highly dependent on the formulation","volume":"174","author":"Ohashi-Doi","year":"2017","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib16","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2500\/ajra.2015.29.4148","article-title":"Clinical considerations in the use of sublingual immunotherapy for allergic rhinitis","volume":"29","author":"Lee","year":"2015","journal-title":"Am J Rhinol Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib17","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1111\/all.12383","article-title":"Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper","volume":"69","author":"Pfaar","year":"2014","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib18","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0091-6749(99)70380-5","article-title":"Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire","volume":"104","author":"Juniper","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0091-6749(94)90349-2","article-title":"Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials","volume":"93","author":"Juniper","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib20","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2222.1991.tb00807.x","article-title":"Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis","volume":"21","author":"Juniper","year":"1991","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib21","doi-asserted-by":"crossref","first-page":"41","DOI":"10.4104\/pcrj.2009.00010","article-title":"The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey","volume":"18","author":"Thomas","year":"2009","journal-title":"Prim Care Respir J"},{"key":"10.1016\/j.jaci.2018.12.1001_bib22","series-title":"ICH Harmonised Tripartite Guideline Topic E2A. Clinical safety data management: definitions and standards for expedited reporting","year":"1994"},{"key":"10.1016\/j.jaci.2018.12.1001_bib23","series-title":"Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases","year":"2008"},{"key":"10.1016\/j.jaci.2018.12.1001_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1398-9995.1998.tb04930.x","article-title":"WHO position paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases","volume":"53","author":"Bousquet","year":"1998","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib25","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jaci.2010.11.035","article-title":"Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults","volume":"127","author":"Nelson","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib26","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.jaci.2013.03.019","article-title":"Randomized controlled trial of a ragweed allergy immunotherapy tablet in North American and European adults","volume":"131","author":"Creticos","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib27","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.anai.2013.03.013","article-title":"Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults","volume":"110","author":"Nolte","year":"2013","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib28","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.anai.2018.02.003","article-title":"Lack of effect of Timothy grass pollen sublingual immunotherapy tablet on birch pollen-induced allergic rhinoconjunctivitis in an environmental exposure unit","volume":"120","author":"Ellis","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib29","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1111\/cea.12331","article-title":"A comparative analysis of symptom and medication scoring methods used in clinical trials of sublingual immunotherapy for seasonal allergic rhinitis","volume":"44","author":"Calderon","year":"2014","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib30","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.anai.2013.11.018","article-title":"Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial","volume":"112","author":"Maloney","year":"2014","journal-title":"Ann Allergy Asthma Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib31","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/all.13155","article-title":"Clinical benefits of treatment with SQ house dust mite sublingual tablet in house dust mite allergic rhinitis","volume":"72","author":"Demoly","year":"2017","journal-title":"Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib32","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.jaci.2012.07.056","article-title":"Birch pollen immunotherapy results in long-term loss of Bet v 1-specific T(H)2 responses, transient T(R)1 activation, and synthesis of IgE-blocking antibodies","volume":"130","author":"Mobs","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib33","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.clinthera.2017.08.003","article-title":"Tolerability of the SQ tree SLIT tablet in adults","volume":"39","author":"Birk","year":"2017","journal-title":"Clin Ther"},{"key":"10.1016\/j.jaci.2018.12.1001_bib34","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/j.jaci.2017.06.014","article-title":"Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy","volume":"141","author":"Valovirta","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib35","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/S0091-6749(99)70380-5","article-title":"Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire","volume":"104","author":"Juniper","year":"1999","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib36","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1016\/0091-6749(94)90349-2","article-title":"Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials","volume":"93","author":"Juniper","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"10.1016\/j.jaci.2018.12.1001_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/j.1365-2222.1991.tb00807.x","article-title":"Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis","volume":"21","author":"Juniper","year":"1991","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.jaci.2018.12.1001_bib38","series-title":"International Conference on Harmonisation. ICH Harmonised Tripartite Guideline Topic E6 (R1): Guideline for Good Clinical Practice","year":"1996"},{"key":"10.1016\/j.jaci.2018.12.1001_bib39","series-title":"Multiple imputation for non response in surveys","author":"Rubin","year":"1987"}],"container-title":["Journal of Allergy and Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919300181?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0091674919300181?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T09:16:45Z","timestamp":1758791805000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0091674919300181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S0091674919300181"],"URL":"https:\/\/doi.org\/10.1016\/j.jaci.2018.12.1001","relation":{},"ISSN":["0091-6749"],"issn-type":[{"value":"0091-6749","type":"print"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The SQ tree SLIT-tablet is highly effective and well tolerated: Results from a randomized, double-blind, placebo-controlled phase III trial","name":"articletitle","label":"Article Title"},{"value":"Journal of Allergy and Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaci.2018.12.1001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc. on behalf of the American Academy of Allergy, Asthma & Immunology.","name":"copyright","label":"Copyright"}]}}